Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Akeso, Everest, GSK, Kelun-Biotech, Kite, Neurophet, P+F Products and Features, Partner Therapeutics, Pfizer, Spinal Resources, Zimmer Biomet.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cerenovus, Clearmind, Coeptis, Diagnoly, GE Healthcare, Guard, Iovance, Lakeshore, Nugen, Polyrizon.
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Aro, Bayer, Denali, Field Medical, Genesys Spine, Hoya Vision, Neovac, Pulse, Roivant, Spruce, Uniqure.
While in 2025 med-tech financings averaged $3.3 billion per month, January 2026 saw the sector bring in $1.52 billion across 39 transactions. It was the lowest monthly total since November 2024’s $924.59 million. However, a number of months last year saw fluctuating values, ranging from $1.65 billion in July to $8.26 billion in December 2025, indicating uncertainty as to how industry financings will shake out this year.
True to its word, Novo Nordisk A/S filed a patent infringement lawsuit in U.S. district court against Hims & Hers Health Inc. over compounded versions of Novo’s semaglutide products.
Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.
Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.
As its GLP-1 rival goes after compounders, Eli Lilly and Co. started the week with news beyond its diabetes and obesity franchise. The company, which disclosed a new agreement with Innovent Biologics Ltd., followed up a short time later with plans to acquire Orna Therapeutics Inc., marking its latest foray in the in vivo therapy space.
RSS
